Sparsentan

Brand name: Filspari

X

Score X — Unknown Risk

There is inadequate information to classify the hepatotoxicity risk of this drug.

The drug may be recently introduced or rarely used in clinical medicine, with insufficient published safety data to assign a risk category.

Primary class Renal Disease
Secondary class IgA nephropathy
FDA approval 2023